APAC CIOOutlook

Advertise

with us

  • Technologies
      • Artificial Intelligence
      • Big Data
      • Blockchain
      • Cloud
      • Digital Transformation
      • Internet of Things
      • Low Code No Code
      • MarTech
      • Mobile Application
      • Security
      • Software Testing
      • Wireless
  • Industries
      • E-Commerce
      • Education
      • Logistics
      • Retail
      • Supply Chain
      • Travel and Hospitality
  • Platforms
      • Microsoft
      • Salesforce
      • SAP
  • Solutions
      • Business Intelligence
      • Cognitive
      • Contact Center
      • CRM
      • Cyber Security
      • Data Center
      • Gamification
      • Procurement
      • Smart City
      • Workflow
  • Home
  • CXO Insights
  • CIO Views
  • Vendors
  • News
  • Conferences
  • Whitepapers
  • Newsletter
  • Awards
Apac
  • Artificial Intelligence

    Big Data

    Blockchain

    Cloud

    Digital Transformation

    Internet of Things

    Low Code No Code

    MarTech

    Mobile Application

    Security

    Software Testing

    Wireless

  • E-Commerce

    Education

    Logistics

    Retail

    Supply Chain

    Travel and Hospitality

  • Microsoft

    Salesforce

    SAP

  • Business Intelligence

    Cognitive

    Contact Center

    CRM

    Cyber Security

    Data Center

    Gamification

    Procurement

    Smart City

    Workflow

Menu
    • Cyber Security
    • Hotel Management
    • Workflow
    • E-Commerce
    • Business Intelligence
    • MORE
    #

    Apac CIOOutlook Weekly Brief

    ×

    Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Apac CIOOutlook

    Subscribe

    loading

    THANK YOU FOR SUBSCRIBING

    Harbour BioMed Secures USD 102.8 Million in Series C Round of Financing

    Clinical stage biopharmaceutical company Harbour BioMed raised USD 102.8 million in a Series C funding round led by new investors, Hudson Bay Capital, followed by OrbiMed, Country Garden VC, GTJA Investment Group, Octagon Capital  

    Harbour BioMed Secures USD 102.8 Million in Series C Round of Financing

    By

    Apac CIOOutlook | Wednesday, July 15, 2020

    Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

    Clinical stage biopharmaceutical company Harbour BioMed raised USD 102.8 million in a Series C funding round led by new investors, Hudson Bay Capital, followed by OrbiMed, Country Garden VC, GTJA Investment Group, Octagon Capital, and Sage Partners, with participation from existing investor Greater Bay Area Investment Fund.

    FREMONT, CA: Clinical stage biopharmaceutical company Harbour BioMed raised USD 102.8 million in Series C funding round led by new investors, Hudson Bay Capital, followed by OrbiMed, Country Garden VC, GTJA Investment Group, Octagon Capital, and Sage Partners, with participation from existing investor Greater Bay Area Investment Fund. The new investment round comes on the heels of a USD 75 million Series B+ financing round which the company closed in March 2020. Harbour BioMed is looking to accelerate the development of its growing portfolio of next-generation biologics targeting cancer, immunologic diseases, and COVID-19.

    "The participation of new and current investors underscores enthusiasm for our clinical portfolio, our antibody discovery and development engine, as well as our strategy to build a leading global biopharmaceutical company," said Dr Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. "We have made great progress with our clinical programs and multiple promising, bi- and monospecific antibodies from our discovery engine that are rapidly moving towards clinical trials. The funding will support final development and initial commercialization of our late stage portfolio and advancement of both our earlier stage discovery and preclinical molecules."

    Harbour BioMed has over 30 programs under its belt, including an anti-CD73 monoclonal antibody (mAb), a bi-specific anti-BCMAxCD3 mAb and, newly announced, an anti-CCR8 mAb, all in preclinical development and targeted at a variety of cancers. The company takes a patient-centric approach to address unmet medical needs across the world. Harbour BioMed currently has five products under clinical development, which include HBM9161 (Batoclimab), a first-in-class fully human anti-FcRn mAb, HBM9036 (Tanfanercept), a novel TNF receptor-1 fragment to treat dry eye disease by inhibiting TNFα, and HBM4003, a next-generation anti-CTLA4 mAb in Phase 1 clinical studies in Australia for the treatment of advanced solid tumors.

    "We are pleased to support Harbour BioMed and its management team to further develop its pipeline of leading immunology and oncology drugs. We believe the company's innovative approach, with next generation technologies that target unmet medical needs, presents an exciting growth opportunity," said Ms Jo-Wen Lin, Asian Healthcare Portfolio Manager at Hudson Bay Capital.

     

    More in News

    Revolutionizing Healthcare Through 5G Technology

    Revolutionizing Healthcare Through 5G Technology

    The Journey Towards Smart City Development

    The Journey Towards Smart City Development

    Harnessing Big Data Analytics to Enhance Business Strategies

    Harnessing Big Data Analytics to Enhance Business Strategies

    AI's Role in Apac's Digital Transformation Journey

    AI's Role in Apac's Digital Transformation Journey

    I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

    Copyright © 2025 APAC CIOOutlook. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Use and Privacy and Anti Spam Policy 

    Home |  CXO Insights |   Whitepapers |   Subscribe |   Conferences |   Sitemaps |   About us |   Advertise with us |   Editorial Policy |   Feedback Policy |  

    follow on linkedinfollow on twitter follow on rss
    This content is copyright protected

    However, if you would like to share the information in this article, you may use the link below:

    https://www.apacciooutlook.com/news/harbour-biomed-secures-usd-1028-million-in-series-c-round-of-financing-nwid-7581.html